Miniatura

Fitxers

695729.pdf (1.51 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-10-14

Llicència de publicació

cc-by (c) García Arumí, José et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/177345

Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naive patients with macular oedema secondary to central retinal vein occlusion (CRVO): a prospective 12-month, single-arm, multicentre trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1155/2018/8310350

Resum

Objectives: to evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design setting and patients: phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016. Intervention: intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing. Main outcomes: mean change in BCVA after 12 months. Results: 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P < 0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported. Conclusions: an aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.

Matèries

Malalties de la retina, Edema, Estudi de casos

Matèries (anglès)

Retinal diseases, Edema, Case studies

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)

Citació

GARCÍA ARUMÍ, José, GÓMEZ ULLA, Francisco, AMPARO, Navea, CERVERA, Enrique, FONOLLOSA, Alex, ARIAS BARQUET, Lluís, ARAIZ, Javier, DONATE, Juan, SUÁREZ DE FIGUEROA, Marta, MANZANAS, Lucía, CRESPI, Jaume, GALLEGO PINAZO, Roberto. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naive patients with macular oedema secondary to central retinal vein occlusion (CRVO): a prospective 12-month, single-arm, multicentre trial. _Journal of Ophthalmology_. 2018. Vol. 2018, núm. 8310350. [consulta: 23 de gener de 2026]. ISSN: 2090-004X. [Disponible a: https://hdl.handle.net/2445/177345]

Exportar metadades

JSON - METS

Compartir registre